Journal Scans
Large Randomized Study of Thymosin alpha 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma
Thymosin Improves Response and Survival in Metastatic Melanoma
M Maio, A Mackiewicz, A Testori, U Trefzer, V Ferraresi, J Jassem, C Garbe, T Lesimple, B Guillot, P Gascon, K Gilde, R Camerini, F Cognetti
20100201
2010 Mar 1
J Clin Oncol
Large Randomized Study of Thymosin alpha 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma
J Clin Oncol. 2010 Mar 1; Epub ahead of print, M Maio, A Mackiewicz, A Testori, U Trefzer, V Ferraresi, J Jassem, C Garbe, T Lesimple, B Guillot, P Gascon, K Gilde, R Camerini, F Cognetti
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Metastatic melanoma has a poor prognosis, even with chemotherapy. In a meta-analysis of phase II studies, mean 1-year survival was 25.5%. Dacarbazine (DTIC) is the benchmark treatment for melanoma. Some studies have shown a survival benefit of combining chemotherapy with immunotherapies such as interferon alfa (IFN-alfa) and interleukin-2 (IL-2), but the toxicity associated with chemoimmunotherapy is much greater than with chemotherapy alone. Novel immunotherapies merit investigation to identify...
